Table 5.
Risk factor | Effect of covariate and risk of deatha |
Effect of antifungal therapyb |
||||||
Baseline risk | Coefficient (β) | SD | OR | P | Coefficient (β) | SD | OR | P |
Age | 0.033 | 0.012 | 1.034 | .004 | 0.064 | 0.024 | 1.066 | .007 |
ANC <200 cells/μL | 2.056 | 0.633 | 7.818 | .001 | 2.623 | 1.234 | 13.777 | .034 |
ARC | 0.114 | 0.234 | 1.120 | .627 | … | … | … | … |
ALC | -.297 | 0.399 | 0.743 | .457 | … | … | … | … |
Platelet count | -.096 | 0.267 | 0.908 | .719 | … | … | … | … |
Bacteremia only | 0.919 | 0.542 | 2.508 | .090 | … | … | … | … |
Fungal infection | 2.751 | 0.665 | 15.666 | <.001 | … | … | … | … |
Voriconazole | … | … | … | … | -2.550 | 0.967 | 0.078 | .008 |
NOTE. The bacteremia-only group did not include patients with a concomitant fungal infection. Fungal groups were those who had a fungal isolate identified in blood, secretions, and/or tissue (seeTable 4). The amphotericin B group does not include liposomal formulations. Voriconazole refers to any voriconazole-containing regimen. Natural log-transformed counts log(ANC+1), log(ARC+1), log(ALC+1), and log(platelet+1) were used to reduce the skewness of these variables. ALC, absolute lymphocyte count; ANC, absolute neutrophil count; ARC, absolute reticulocyte count; OR, odds ratio; SD, standard deviation.
Includes age, ANC, ARC, ALC, Platelet count, bacteremia-only infection, and fungal infection.
After fungal infection was found to be an independent variable predicting probability of death, a separate analysis was performed to assess the effect of voriconazole vs amphotericin B as a predictor of death (includes age, ANC, and antifungal therapy defined by 0 if amphotericin B was used and 1 if a voriconazole-containing regimen was used). There were insufficient numbers of patients receiving echinocandins to be included in this analysis. Covariates not statistically significant in the first analysis were not included in the antifungal analysis.